1. Recent Advances in the Treatment of Lymphoma

3. Program Topics

4. Mantle Cell Lymphoma

5. First-Line and Second-Line Therapy[a,b]

6. Risk Stratification

7. Induction: Lenalidomide Plus Rituximab

8. Induction: Addition of Cytarabine to Immunochemotherapy Pre-ASCT

9. 5-Year TTF

10. Induction: 15-Year Follow-Up of Nordic MCL2

11. Relapse: Lenalidomide vs Investigator’s Choice

12. Relapse: Ibrutinib vs Temsirolimus

13. Relapse: Post-Ibrutinib Outcomes

14. Recent Advances in the Treatment of Lymphoma

15. DLBCL: Evaluation

16. Biomarker Frequency

17. Double Hit vs Double Protein (Expresser)

18. The Current Standard of Care

19. Strategies for Improving Outcomes for the Other 40%

20. EFS24

21. Examples of New Regimens

22. R(X) vs R-CHOP

23. R(X) vs R-CHOP (cont)

24. What Have We Learned?

25. Issues for Next Trials

26. Abbreviations

27. Abbreviations (cont)

28. Abbreviations (cont)